Therapeutic Asset Ratings
228 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Calcium folinate pentahydrate
Serum Ferritin
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Capecitabine
Acute Leukemia
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Capecitabine
Immune-related Adverse Event
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Capecitabine
Malignant Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Capecitabine
Serum Ferritin
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
cht102 allogeneic car t cells
Mesothelin Positive Tumors
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Docetaxel
Analgesia
Tianjin Medical University Cancer Institute and Hospital
D
(30)
Docetaxel
Delirium
Tianjin Medical University Cancer Institute and Hospital
D
(30)
Eloxatin
Acute Leukemia
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Eloxatin
Immune-related Adverse Event
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Eloxatin
Malignant Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Eloxatin
Serum Ferritin
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Enituzumab
Breast Carcinoma
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Epirubicin
Analgesia
Tianjin Medical University Cancer Institute and Hospital
D
(30)
Epirubicin
Delirium
Tianjin Medical University Cancer Institute and Hospital
D
(30)
FLUOROURACILUM
Acute Leukemia
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
FLUOROURACILUM
Immune-related Adverse Event
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
FLUOROURACILUM
Malignant Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
FLUOROURACILUM
Serum Ferritin
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
LENVATINIB
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Pyrotinib
RWS
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Romiplostim
Chemotherapy-Induced Toxicity
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
T-Dxd
HER2 Overexpression
Tianjin Medical University Cancer Institute and Hospital
D
(30)
Trastuzumab Emtansine For
HER2 Positive Breast Carcinoma
Tianjin Medical University Cancer Institute and Hospital
N/A
D
(30)
Efgbemalenograstim Alfa
Non-Small Cell Lung Carcinoma
Tianjin Medical University Cancer Institute and Hospital
P2
NR
(0)
Showing 201 to 225 of 228 assets
Previous
Page 9 of 10
Next